JAKARTA, June 3, 2026 – PT Pyridam Farma Tbk (IDX: PYFA) recorded positive performance in the first quarter of 2026 compared to the same period last year. The Company posted net revenue of Rp766.53 billion, representing an 11.8% increase from Rp685.46 billion in Q1 2025.

In line with this revenue growth, the Company’s gross profit rose by 6.9% to Rp192.8 billion. This was driven by manufacturing efficiencies and increased productivity, which successfully offset rising raw material costs and market pricing pressures.

Furthermore, the Company’s profitability demonstrated increasingly solid performance, with EBITDA surging by 30% compared to Q1 2025. This growth was accompanied by an expanded EBITDA margin, which improved to 9.5% from 8.2% in the prior year’s corresponding period.

This positive trend reflects the effectiveness of the Company’s ongoing business transformation strategy. The robust financial performance was significantly bolstered by a stronger pharmaceutical product portfolio, an optimized distribution network, and a growing contribution from PYFA’s integrated healthcare business line.

Sinta Ningsih, Director of PYFA, stated that the strong performance earlier this year highlights an increasingly solid business foundation and serves as positive momentum to drive sustainable growth moving forward.

“In addition to the sustained contributions from our primary growth pillar—CDMO services—revenue growth was also fueled by the strong performance of several highly licensed pharmaceutical products that offer greater value and better margins,” said Sinta Ningsih. “Correspondingly, the progress of our various strategic investments, including our subsidiary’s Line 3 production facility, signals a promising outlook for the Company’s future growth. We are optimistic that focusing on a high-value product portfolio while strengthening our manufacturing capabilities will significantly enhance PYFA’s long-term competitiveness.”

Beyond the Line 3 expansion at its subsidiary, PT Ethica Industri Farmasi, PYFA is currently preparing for the construction of Production Lines 4 and 5. These new facilities are expected to significantly boost production capacity and reinforce the Company’s ability to meet the demands of the national pharmaceutical market.

Looking ahead, the Company is optimistic about sustaining this growth momentum through a combined strategy of high-license product innovation, a targeted focus on specific therapeutic areas, manufacturing capacity expansion, healthcare network strengthening, and the development of a business portfolio focused on segments with high growth potential.

About PYFA

PT Pyridam Farma Tbk, also known as PYFA, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates several business units producing prescription medicines in various forms, including tablets, capsules, creams, and injections. PYFA also has several well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Multipack.

Media Relations

Leilanie Nadia Kusuma
Head of Corporate Communications
Website : www.pyfa.co.id
Email : corcomm@pyfa.co.id